Dry EyesNCT01933165
Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
A study testing LipiView in people with Dry Eyes, run by Singapore National Eye Centre at 1 site in Singapore.
Trial summary
Dry eye clinical research is limited to follow up of disease progression. While a large catalogue of tests, such as corneal staining grading, tear break up time (TBUT) and Schirmer's test, is available, objective assessments demonstrate poor to moderate repeatability. Read more about this study
- Who is it for?
- Ages 21 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Dry Eyes
- What is being tested?
- LipiView
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSingapore
- Study dates
- Sep 2013to Feb 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Volunteers that are medically fit and willing to participate in this study.
Who cannot join
- No eye surgery done within the previous 3 months
- Active ocular surface conditions such as infection or pterygium that may affect tear film stability.
- Any other specified reason as determined by clinical investigator.
Trial locations and contacts
1 site in 1 country.
Singapore1 site
Singapore Eye Research Institute
Singapore, Singapore, 168751
About this study
Official title: Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
Dry eye clinical research is limited to follow up of disease progression. While a large catalogue of tests, such as corneal staining grading, tear break up time (TBUT) and Schirmer's test, is available, objective assessments demonstrate poor to moderate repeatability. Among these assessments, TBUT has the best repeatability while the Schirmer's test shows good repeatability for more severe forms of the disease.1 As such, currently, most research outcomes are based on subjective patient complaints rather than objective assessment of the condition.
LipiView Ocular Surface Interferometer (LipiView) is a HSA-approved imaging device that has the ability to assess optical interference pattern produced by light reflected off the tear film in a safe and non-invasive manner.2 Software analysis of the image then measures the tear LLT, which is used to objectively quantify the diagnosis of lipid-deficient dry eye.
Read more
This current study aims to investigative the inter and intra-examiner reproducibility of measuring tear lipid layer thickness (LLT) with LipiView, which is used in our current clinical setting. LipiView has not been evaluated on its reproducibility of measuring tear lipid layer thickness. The study will also assess for correlation between the magnitude of tear LLT and the inter and intra-examiner reproducibility of LipiView.
Once this method is found to be repeatable, this can be used in future clinical settings and trials as an additional tool to investigate dry eye treatments.
Read the detailed description
This study will be conducted in compliance with the protocol, SGCP and the applicable regulatory requirements.
Dry eye is a condition that affects 5-35% of the population.11 Common symptoms of this condition include eye irritation, heaviness of the eyelids, visual disturbances, tearing and light sensitivity.12 This significantly impacts the quality of life and vision of dry eye patients. In addition, there is a significant socioeconomic burden. In 2009, 54,051 patients sought treatment for dry eye in the Singapore National Eye Centre (SNEC). In total, the costs for dry eye medication amounted to $181,354.17.14 Additionally, dry eye affects work productivity which further adds on to the socioeconomic burden.15
Currently, the diagnosis and assessment of dry eye is hindered by tests that have poor repeatability, some of which cause discomfort due to their invasiveness. As a result most clinical studies involving dry eye treatment rely on symptomatic improvements as a primary outcome measure. However, symptomatic improvements are a poor measure in determining treatment effectiveness because with disease progression, the eye becomes desensitized from nerve damage. Also, it is common for patients to feel a reduction of discomfort of the eye before objective improvements can be noted by the clinician. An assessment based on symptoms alone is therefore inappropriate.13
Over the last few years, SNEC/SERI has built up a dedicated team of dry eye researchers for trials and evaluation of diagnostic devices. There is an increasing interest internationally, especially from industry, to partner us for testing of commercial products.
The LipiView Ocular Surface Interferometer is a HSA-approved imaging device that allows clinicians evaluate the characteristics and thickness of the tear lipid layer thickness (LLT) in a safe and non-invasive manner. The device utilizes white light from a LED source that is directed at the tear film over the inferior corneal region. Reflected light is captured by a high resolution camera and the optical inference pattern is evaluated by software to determine the LLT. 2 It also was found to correlate with other dry eye diagnostic tests, such as tear film break-up time (TBUT), Schirmer's test and corneal staining 3,4,5,6. LLT is also reported to better correlate with symptoms than other objective dry eye tests. 2
While several studies have investigated and shown the association between dry eye syndrome and low LLT 2,7,8,9, it is not known if LipiView would be able to make reproducible measurements of LLT for the objective diagnosis of dry eye syndrome.
Clinical importance Should this modality of imaging be shown to be repeatable, it can be incorporated into current protocol/workflow for assessment and monitoring of dry eye and treatment progress in our centre, as well as enhancing our capability to perform clinical trials and increase our international reputation.
Study Objectives and Purpose The primary purpose is to evaluate intra-examiner repeatability of the LipiView Ocular Surface Interferometer (LipiView) for imaging tear lipid layer thickness.
Study design:
Prospective study
Rationale:
Repeatability is an important issue in the objective assessment of dry eye. There is lack of studies that investigate LipiView for assessment of the tear film lipid layer thickness in dry eyes. LipiView is potentially useful as a non-invasive procedure for objective measurements of dry eyes.
Methods:
Participants and target sample size 20 healthy volunteers will be recruited for this study. During recruitment, a simple questionnaire is given to confirm for the absence of any dry eye symptoms. Each volunteer will also be given a study serial number to ensure anonymity.
All 20 volunteers will participate in the LipiView repeatability and inter-rater agreement study.
Visit schedules One visit is required for participants.
Duration of study:
10 months.
Procedures:
- Assessment of Dry Eye Symptoms Participants will be asked to score and fill up a dry eye questionnaire that assesses the symptomatic severity of dry eyes in the participant and the extent of its disruption to daily activities. Basic biodata such as age, race, gender will also be recorded.
- LipiView Ocular Surface Interferometer Tear Lipid Layer Thickness Measurement During the measurement of each eye, the participants place their chins on a chin rest and look at a single white light source for 30 seconds. During this period, participants are encouraged to blink freely at a comfortable rate which the assessor measures the LLT. Afterwards, the aforementioned steps will be repeated for the same eye by another assessor after a 5 minutes interval. Assessor 1 will perform the measurement at time 0 min, 10min and 20min while Assessor 2 will perform the measurement at time 5 min, 15 min, 25min. Similar steps would be taken for the other eye. Therefore, 12 measurements would be taken altogether per participant. Between measurements, participants are advised not to rub or touch their eyes, or instill any eye drops or ointment. Assessment of fluorescein tear break up time and corneal staining will be conducted only after LipiView LLT measurement.
- Fluorescein Dye Tear Break-up Time (TBUT) Fluorescein dye is introduced onto the lower eyelid by a wetted fluorescein strip. The tear film will then be observed with blue light using a slit lamp to the point where it breaks. The time from the previous blink to the breaking of the tear film will be recorded to the nearest second.
- Fluorescein Dye Corneal Staining After fluorescein dye is introduced, the cornea will be examined for green stains indicating epithelial erosion, a sign of damage due to dryness. The number of green stains and their location on the cornea (superior, central, inferior, temporal, nasal fields) will be recorded.
- Conditions
- Dry Eyes
- Being tested
- LipiView
- Keywords
- Dry Eyes, LipiView, Lipid thickness
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LipiViewDevice
| Study group | Role | What they receive |
|---|---|---|
| LipiView | Other | Not described Receives: Device: LipiView |
What is being measured
The primary outcome is the main question the study is designed to answer.
The repeatability of objective tear lipid layer thickness measurements of LipiView from the same examiner.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2013 (estimated)
- Study startSep 2013
- Primary completionFeb 2014
- Study completionFeb 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry EyesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Singapore National Eye Centre
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Louis Tong, Singapore National Eye Centre
- Investigators
- Louis Tong, PhD, Principal investigator, Singapore National Eye Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01933165
- Sponsor's protocol ID
- R1028/43/2013
- Other IDs
- 2013/327/A
- Status last verified
- Jun 2014
- First submitted
- 28 Aug 2013
- Last updated
- 10 Jun 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness
- ClinicalTrials.gov ID
- NCT01933165
- Acronym / sponsor ID
- R1028/43/2013
- Conditions
- Dry Eyes
- Keywords
- Dry Eyes, LipiView, Lipid thickness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Singapore National Eye CentreOther government
- Study start
- Sep 2013
- Primary completion
- Feb 2014 (actual)
- Study completion
- Feb 2014 (actual)
- First posted
- 2 Sep 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dry eye clinical research is limited to follow up of disease progression. While a large catalogue of tests, such as corneal staining grading, tear break up time (TBUT) and Schirmer's test, is available, objective assessments demonstrate poor to moderate repeatability. Among these assessments, TBUT has the best repeatability while the Schirmer's test shows good repeatability for more severe forms of the disease.1 As such, currently, most research outcomes are based on subjective patient complaints rather than objective assessment of the condition.
LipiView Ocular Surface Interferometer (LipiView) is a HSA-approved imaging device that has the ability to assess optical interference pattern produced by light reflected off the tear film in a safe and non-invasive manner.2 Software analysis of the image then measures the tear LLT, which is used to objectively quantify the diagnosis of lipid-deficient dry eye.
This current study aims to investigative the inter and intra-examiner reproducibility of measuring tear lipid layer thickness (LLT) with LipiView, which is used in our current clinical setting. LipiView has not been evaluated on its reproducibility of measuring tear lipid layer thickness. The study will also assess for correlation between the magnitude of tear LLT and the inter and intra-examiner reproducibility of LipiView.
Once this method is found to be repeatable, this can be used in future clinical settings and trials as an additional tool to investigate dry eye treatments.
Detailed description
This study will be conducted in compliance with the protocol, SGCP and the applicable regulatory requirements.
Dry eye is a condition that affects 5-35% of the population.11 Common symptoms of this condition include eye irritation, heaviness of the eyelids, visual disturbances, tearing and light sensitivity.12 This significantly impacts the quality of life and vision of dry eye patients. In addition, there is a significant socioeconomic burden. In 2009, 54,051 patients sought treatment for dry eye in the Singapore National Eye Centre (SNEC). In total, the costs for dry eye medication amounted to $181,354.17.14 Additionally, dry eye affects work productivity which further adds on to the socioeconomic burden.15
Currently, the diagnosis and assessment of dry eye is hindered by tests that have poor repeatability, some of which cause discomfort due to their invasiveness. As a result most clinical studies involving dry eye treatment rely on symptomatic improvements as a primary outcome measure. However, symptomatic improvements are a poor measure in determining treatment effectiveness because with disease progression, the eye becomes desensitized from nerve damage. Also, it is common for patients to feel a reduction of discomfort of the eye before objective improvements can be noted by the clinician. An assessment based on symptoms alone is therefore inappropriate.13
Over the last few years, SNEC/SERI has built up a dedicated team of dry eye researchers for trials and evaluation of diagnostic devices. There is an increasing interest internationally, especially from industry, to partner us for testing of commercial products.
The LipiView Ocular Surface Interferometer is a HSA-approved imaging device that allows clinicians evaluate the characteristics and thickness of the tear lipid layer thickness (LLT) in a safe and non-invasive manner. The device utilizes white light from a LED source that is directed at the tear film over the inferior corneal region. Reflected light is captured by a high resolution camera and the optical inference pattern is evaluated by software to determine the LLT. 2 It also was found to correlate with other dry eye diagnostic tests, such as tear film break-up time (TBUT), Schirmer's test and corneal staining 3,4,5,6. LLT is also reported to better correlate with symptoms than other objective dry eye tests. 2
While several studies have investigated and shown the association between dry eye syndrome and low LLT 2,7,8,9, it is not known if LipiView would be able to make reproducible measurements of LLT for the objective diagnosis of dry eye syndrome.
Clinical importance Should this modality of imaging be shown to be repeatable, it can be incorporated into current protocol/workflow for assessment and monitoring of dry eye and treatment progress in our centre, as well as enhancing our capability to perform clinical trials and increase our international reputation.
Study Objectives and Purpose The primary purpose is to evaluate intra-examiner repeatability of the LipiView Ocular Surface Interferometer (LipiView) for imaging tear lipid layer thickness.
Study design:
Prospective study
Rationale:
Repeatability is an important issue in the objective assessment of dry eye. There is lack of studies that investigate LipiView for assessment of the tear film lipid layer thickness in dry eyes. LipiView is potentially useful as a non-invasive procedure for objective measurements of dry eyes.
Methods:
Participants and target sample size 20 healthy volunteers will be recruited for this study. During recruitment, a simple questionnaire is given to confirm for the absence of any dry eye symptoms. Each volunteer will also be given a study serial number to ensure anonymity.
All 20 volunteers will participate in the LipiView repeatability and inter-rater agreement study.
Visit schedules One visit is required for participants.
Duration of study:
10 months.
Procedures:
- Assessment of Dry Eye Symptoms Participants will be asked to score and fill up a dry eye questionnaire that assesses the symptomatic severity of dry eyes in the participant and the extent of its disruption to daily activities. Basic biodata such as age, race, gender will also be recorded.
- LipiView Ocular Surface Interferometer Tear Lipid Layer Thickness Measurement During the measurement of each eye, the participants place their chins on a chin rest and look at a single white light source for 30 seconds. During this period, participants are encouraged to blink freely at a comfortable rate which the assessor measures the LLT. Afterwards, the aforementioned steps will be repeated for the same eye by another assessor after a 5 minutes interval. Assessor 1 will perform the measurement at time 0 min, 10min and 20min while Assessor 2 will perform the measurement at time 5 min, 15 min, 25min. Similar steps would be taken for the other eye. Therefore, 12 measurements would be taken altogether per participant. Between measurements, participants are advised not to rub or touch their eyes, or instill any eye drops or ointment. Assessment of fluorescein tear break up time and corneal staining will be conducted only after LipiView LLT measurement.
- Fluorescein Dye Tear Break-up Time (TBUT) Fluorescein dye is introduced onto the lower eyelid by a wetted fluorescein strip. The tear film will then be observed with blue light using a slit lamp to the point where it breaks. The time from the previous blink to the breaking of the tear film will be recorded to the nearest second.
- Fluorescein Dye Corneal Staining After fluorescein dye is introduced, the cornea will be examined for green stains indicating epithelial erosion, a sign of damage due to dryness. The number of green stains and their location on the cornea (superior, central, inferior, temporal, nasal fields) will be recorded.
Study design
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| LipiView | Other | Device: LipiView |
Who may qualify
- Ages
- 21 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Volunteers that are medically fit and willing to participate in this study.
Key exclusion criteria (3 listed)
- No eye surgery done within the previous 3 months
- Active ocular surface conditions such as infection or pterygium that may affect tear film stability.
- Any other specified reason as determined by clinical investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LipiView | Device | LipiView |
Primary outcome
The repeatability of objective tear lipid layer thickness measurements of LipiView from the same examiner.
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2014.
Related trials for Dry Eyes
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Louis Tong, PhD principal investigator
Singapore National Eye Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LipiView in people with Dry Eyes, run by Singapore National Eye Centre at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The repeatability of objective tear lipid layer thickness measurements of LipiView from the same examiner. (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2014.